Lupin Pharmaceuticals

Lupin Pharmaceuticals Inc. (“Lupin”) is dedicated to delivering high-quality, branded and generic pharmaceutical products trusted by healthcare professionals and patients across the United States (US). Lupin is currently the 4th largest generic pharmaceutical company in the US by prescriptions dispensed (5.2% generic market share — IMS Health National Prescription Audit, MAT March 2017).

Lupin’s journey began in 2003 with three Baltimore-based employees and one US generic product approval and now markets a total of 140 generic products. As of March 2017, Lupin is the market share leader in 46 generic products and amongst the Top 3 in 79 products in the US (IMS Generics Module, Quarterly Data March 2017). Last fiscal year, Lupin generated a record $1.1 billion in net revenues, contributing 37% of the Company’s global revenues. Lupin completed its acquisition of privately held US based Gavis Pharmaceuticals, LLC and Novel Laboratories Inc. in 2015. Novel has since been renamed Lupin Somerset. The Gavis/ Novel acquisition positions Lupin as the 4th largest pipeline of ANDA filings with the US Food and Drug Administration (FDA). Lupin has brought significant, high-quality, affordable medications to the market which has helped fuel the growth of its business.

Today, Lupin has 28 pending First-to-File (FTF) products and a total of 154 ANDA filings pending FDA approval with a deep pipeline of products under development for the US market. Lupin has a strong corporate culture of excellence in place, ensuring strict adherence to FDA regulations year after year.

The momentum of Lupin’s sustained growth year over year is a result of a valuable pipeline, solid customer relationships and flawless execution. Last fiscal year, Lupin launched 18 new products. The majority of Lupin’s products are vertically integrated which ensures quality control throughout each step of product development and manufacturing. This gives Lupin an unparalleled advantage over its competitors, as it is able to control its supply chain while offering competitive pricing.

Recent generic launches include Clobetasol Topical Solution USP, 0.05% (Temovate®), Desvenlafaxine ER Tablets (Pristiq®), Paroxetine HCl ER Tablets (Paxil CR®), Hydrocodone Bitartrate & Acetaminophen Tablets USP (Xodol®), Mibelas™ 24 Fe (Minastrin® 24 Fe), Abacavir and Lamivudine Tablets USP (Epzicom®), Desoximetasone Ointment USP, 0.05% and 0.25% (Topicort®), and Desoximetasone Cream USP, 0.05% and 0.25% (Topicort® LP Emollient Cream (0.05%), Topicort® Cream (0.25%)). Lupin aims to continue to strengthen its market presence by launching new products and expanding its pipeline to offer medications in new therapeutic areas such as Dermatology, Pediatrics, Women’s Health, Inhalation and Complex Injectables.

Lupin’s steadfast commitment to quality and reliability has resulted in the company consistently delivering high-quality products. Lupin’s ongoing investment in technological capabilities will position the company to ensure customer satisfaction for years to come.